Get the Stockscreener App
0.7826
6.51%
-0.0545
After Hours:
.78
-0.0026
-0.33%
Context Therapeutics Inc Stock (CNTX) Latest News
Centrexion stock hits 52-week low at $0.79 amid market challenges - MSN
Context Therapeutics Inc (CNTX) Stock: A SWOT Analysis - The News Heater
Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial - MyChesCo
Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) PT at $6.33 - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too - MSN
Franklin Resources Inc. Acquires Additional Shares in Context Th - GuruFocus.com
Centrexion stock hits 52-week low at $0.9 amid market challenges - Investing.com India
Centrexion stock hits 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
Context Therapeutics Welcomes Andy Pasternak as New Chairman of the Board - MSN
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update - MarketBeat
Context Therapeutics’ (CNTX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Context doses first subject in Phase I cancer trial of CTIM-76 - Yahoo Finance
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from D. Boral Capital - MarketBeat
Context Therapeutics Advances CTIM-76 in Clinical Pipeline - TipRanks
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 - GlobeNewswire
Context Therapeutics Launches Phase 1 Trial for Novel Cancer Treatment CTIM-76 - StockTitan
Context Therapeutics Appoints Andy Pasternak as Chairman - TipRanks
Context Therapeutics appoints new chairman Andy Pasternak - Investing.com India
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors - The Manila Times
Context Therapeutics Names Former Horizon Executive Andy Pasternak as Board Chairman - StockTitan
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.80 Average Target Price from Brokerages - Defense World
Geode Capital Management LLC Cuts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Geode Capital Management LLC Purchases 70,070 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World
JMP Securities Begins Coverage on Context Therapeutics (NASDAQ:CNTX) - Defense World
Context Therapeutics (NASDAQ:CNTX) Raised to Strong-Buy at Citizens Jmp - Defense World
MPM BIOIMPACT LLC Acquires Significant Stake in Context Therapeu - GuruFocus.com
Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Citizens Jmp - MarketBeat
SpringWorks Therapeutics Stock Gets A RS Rating Lift - MSN
Aclaris Therapeutics Awards Stock Options to Attract Top Talent - MSN
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Earns Outperform Rating from Analysts at JMP Securities - MarketBeat
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Analyst sees upside in Context Therapeutics stock—next-gen antibodies in spotlight - Investing.com Nigeria
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Philly’s year in biopharma: a look back at 2024 - MSN
State Street Corp Purchases 19,800 Shares of Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World
Cal-Maine Foods IN (CALM-Q) QuotePress Release - The Globe and Mail
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):